Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Dec 6;22(7):1561–1570. doi: 10.1093/annonc/mdq624

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Association of BRCA1-like^CGH classification with outcome after high-dose platinum-based (HD-PB) chemotherapy and conventional chemotherapy in all patients of the stage III series and the triple-negative subgroup. Kaplan–Meier survival curves according to the BRCA1 classification of patients who had been randomly assigned between HD chemotherapy and conventional chemotherapy. (A) Recurrence-free survival of non-BRCA1-like^CGH HER2-negative patients. (B) Recurrence-free survival of BRCA1-like^CGH HER2-negative patients. (C) Overall survival of non-BRCA1-like^CGH HER2-negative patients. (D) Overall survival of BRCA1-like^CGH HER2-negative patients. (E) Recurrence-free survival of non-BRCA1-like^CGH ‘triple-negative’ patients. (F) Recurrence-free survival of BRCA1-like^CGH triple-negative patients. CGH, comparative genomic hybridisation.